We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+34.89%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$135M
AUM Growth
+$26.2M
Cap. Flow
-$1.89M
Cap. Flow %
-1.39%
Top 10 Hldgs %
91.35%
Holding
24
New
1
Increased
4
Reduced
1
Closed
6

Top Buys

Rank Stock Value
1
XCUR icon
Exicure
XCUR
+$3.49M
2
ENTX icon
Entera Bio
ENTX
+$2.9M
3
ABEO icon
Abeona Therapeutics
ABEO
+$1.41M
4
CRBP icon
Corbus Pharmaceuticals
CRBP
+$296K
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$219K

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$4.17M
2
MO icon
Altria Group
MO
+$3.68M
3
DD icon
DuPont de Nemours
DD
+$992K
4
GLMD icon
Galmed Pharmaceuticals
GLMD
+$696K
5
ECOR icon
electroCore
ECOR
+$481K

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Financials 6.29%
3 Materials 2.58%
4 Communication Services 2.15%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$46.6M 34.43%
857,494
– –
CRBP icon
2
Corbus Pharmaceuticals
CRBP
$170M
$27.6M 20.34%
168,196
+2,000
+1% +$296K
APLT
3
DELISTED
Applied Therapeutics
APLT
$12.7M 9.41%
467,071
– –
ABEO icon
4
Abeona Therapeutics
ABEO
$345M
$9.35M 6.9%
114,391
+20,000
+21% +$1.41M
BX icon
5
Blackstone
BX
$104B
$8.52M 6.29%
153,000
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.22M 3.85%
11,675
– –
XCUR icon
7
Exicure
XCUR
$11.2M
$3.65M 2.7%
+8,519
New +$3.49M
ENTX icon
8
Entera Bio
ENTX
$101M
$3.6M 2.66%
1,741,363
+1,265,823
+266% +$2.9M
ALDX icon
9
Aldeyra Therapeutics
ALDX
$91.7M
$3.31M 2.44%
569,405
+37,837
+7% +$219K
KBA icon
10
KraneShares Bosera MSCI China A 50 Connect Index ETF
KBA
$150M
$3.14M 2.32%
96,000
– –
LUMN icon
11
Lumen
LUMN
$6.53B
$2.91M 2.15%
220,000
– –
AVXL icon
12
Anavex Life Sciences
AVXL
$222M
$1.88M 1.39%
724,205
– –
DOW icon
13
Dow Inc
DOW
$21.6B
$1.64M 1.21%
30,000
– –
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
$1.59M 1.18%
7,594
– –
SNGX icon
15
Soligenix
SNGX
$5.5M
$1.14M 0.84%
3,286
– –
DD icon
16
DuPont de Nemours
DD
$18.6B
$963K 0.71%
11,950
-11,950
-50% -$992K
CTVA icon
17
Corteva
CTVA
$59.7B
$887K 0.66%
30,000
– –
OTRK
18
DELISTED
Ontrak
OTRK
$702K 0.52%
478
– –
ECOR icon
19
electroCore
ECOR
$51.4M
– –
-14,671
Closed -$481K
GLMD icon
20
Galmed Pharmaceuticals
GLMD
$3.94M
– –
-809
Closed -$696K
KRYS icon
21
Krystal Biotech
KRYS
$9.88B
– –
-120,212
Closed -$4.17M
LPCN icon
22
Lipocine
LPCN
$17.1M
– –
-2,941
Closed -$141K
MO icon
23
Altria Group
MO
$122B
– –
-90,000
Closed -$3.68M
NTBL
24
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-611
Closed -$29K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Knoll Capital Management held 24 positions worth $135M, up 24% from $109M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Knoll Capital Management's Q4 2019 filing shows 1 new, 4 increased, 1 reduced and 6 closed positions. Its largest new stake was Exicure: 8,519 shares worth $3.65M. The largest sale was Krystal Biotech, an estimated $4.17M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 81% a quarter earlier, followed by Financials and Materials.

  • Knoll Capital Management's largest Q4 2019 buy was Exicure: 8,519 shares worth $3.65M.
  • Knoll Capital Management added most to Entera Bio in Q4 2019, an estimated $2.9M increase.
  • Knoll Capital Management's biggest Q4 2019 reduction was DuPont de Nemours, cutting an estimated $992K.
  • Knoll Capital Management fully exited Krystal Biotech in Q4 2019, selling an estimated $4.17M.
  • Knoll Capital Management's ten largest holdings make up 91% of its $135M portfolio in Q4 2019.
  • Knoll Capital Management opened 1 new position and closed 6 in Q4 2019.
  • Knoll Capital Management's portfolio value rose 24% quarter-over-quarter to $135M.

Based on Knoll Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.